For patients who already have flow cytometry, can you just run the drug sensitivity profile?

Yes, our AI-driven Drug Response Predictions Only (DRP) service is available starting May 2024. This service focuses solely on the drug prediction aspect, providing you with insights without the flow cytometry and PARR results.

Other Questions

Back to Help Center

For the blood tube submission– Do you request that on every patient, even if they don't have a leukemic component? And what type of blood tube do you request we send the sample in?

We require at least 2 mL of whole blood in an EDTA-treated tube.

Is this test available outside the US? Could I order the test?

Because we require live, fresh, cancer cells within 24-48 hours of doing a fine needle aspiration, we are ONLY offering our services in North America at this time. If you already had an experience of sending biopsy samples to the US in 24-48 hours, we could discuss the work further. Please contact info@imprimedicine.com.

What does flow cytometry tell me about my patient’s specimen?

ImpriMed’s flow cytometry report provides comprehensive information about the specimen’s immunophenotype. B-cell and T-cell immunophenotypes are useful in determining lymphoma/leukemia subtype and prognosis. In addition, our panel of ten antigens can also be used in the diagnosis of T-zonal lymphoma, acute leukemia, and other diseases. Antigens levels reported are: CD21, CD79a, CD3, CD4, CD8, CD5, CD45, CD34, CD14, and MHC class II. For more information, see: https://pubmed.ncbi.nlm.nih.gov/26953614/

What does the ImpriMed Personalized Prediction Profile include?

The Personalized Prediction Profile includes our Immunoprofile report and anticancer drug response predictions generated by artificial intelligence models. The predictions include estimates of both (1) the likelihood of a positive clinical response (partial response/ complete remission) to individual anticancer drugs and (2) the likelihood complete remission after 1 or 2 cycles of CHOP therapy, and the likelihood of early relapse after a successful CHOP regimen. Outcome predictions are currently provided for 13 individual drugs that are commonly used in many first-line and rescue protocols for the treatment of canine lymphoma (including CHOP, LOPP, MOPP, LPP, Tavonea only, etc…). Predictions are included for Doxorubicin, Cyclophosphamide, Vincristine, Vinblastine, Prednisone, Rabacfosadine (Tanovea®), L-Asparaginase, Lomustine, Mitoxantrone, Mechlorethamine, Dexamethasone, Chlorambucil, and Melphalan.

Does pet insurance cover ImpriMed?

Most pet insurance plans that cover cancer care will typically cover ImpriMed’s services. Please check with your insurance representative to see if your plan can cover the services.